117 related articles for article (PubMed ID: 25656700)
1. The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.
Cividini F; Pesi R; Chaloin L; Allegrini S; Camici M; Cros-Perrial E; Dumontet C; Jordheim LP; Tozzi MG
Biochem Pharmacol; 2015 Mar; 94(2):63-8. PubMed ID: 25656700
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening.
Jordheim LP; Marton Z; Rhimi M; Cros-Perrial E; Lionne C; Peyrottes S; Dumontet C; Aghajari N; Chaloin L
Biochem Pharmacol; 2013 Feb; 85(4):497-506. PubMed ID: 23220537
[TBL] [Abstract][Full Text] [Related]
3. Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies.
Galmarini CM; Jordheim L; Dumontet C
Leuk Lymphoma; 2003 Jul; 44(7):1105-11. PubMed ID: 12916861
[TBL] [Abstract][Full Text] [Related]
4. IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
Cividini F; Filoni DN; Pesi R; Allegrini S; Camici M; Tozzi MG
Biochim Biophys Acta; 2015 Jul; 1850(7):1354-61. PubMed ID: 25857773
[TBL] [Abstract][Full Text] [Related]
5. Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5'-nucleotidase II.
Cividini F; Cros-Perrial E; Pesi R; Machon C; Allegrini S; Camici M; Dumontet C; Jordheim LP; Tozzi MG
Int J Biochem Cell Biol; 2015 Aug; 65():222-9. PubMed ID: 26079827
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of β-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies.
Meurillon M; Marton Z; Hospital A; Jordheim LP; Béjaud J; Lionne C; Dumontet C; Périgaud C; Chaloin L; Peyrottes S
Eur J Med Chem; 2014 Apr; 77():18-37. PubMed ID: 24607586
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of cytosolic 5'-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells.
Careddu MG; Allegrini S; Pesi R; Camici M; Garcia-Gil M; Tozzi MG
Biochim Biophys Acta; 2008 Aug; 1783(8):1529-35. PubMed ID: 18445485
[TBL] [Abstract][Full Text] [Related]
8. Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach.
Marton Z; Guillon R; Krimm I; Preeti ; Rahimova R; Egron D; Jordheim LP; Aghajari N; Dumontet C; Périgaud C; Lionne C; Peyrottes S; Chaloin L
J Med Chem; 2015 Dec; 58(24):9680-96. PubMed ID: 26599519
[TBL] [Abstract][Full Text] [Related]
9. Lead optimization and biological evaluation of fragment-based cN-II inhibitors.
Guillon R; Rahimova R; Preeti ; Egron D; Rouanet S; Dumontet C; Aghajari N; Jordheim LP; Chaloin L; Peyrottes S
Eur J Med Chem; 2019 Apr; 168():28-44. PubMed ID: 30798051
[TBL] [Abstract][Full Text] [Related]
10. F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation.
Jordheim LP; Cros E; Galmarini CM; Dumontet C; Bretonnet AS; Krimm I; Lancelin JM; Gagnieu MC
Nucleosides Nucleotides Nucleic Acids; 2006 Mar; 25(3):289-97. PubMed ID: 16629121
[TBL] [Abstract][Full Text] [Related]
11. Nucleotide and nucleoside analogues as inhibitors of cytosolic 5'-nucleotidase I from heart.
Garvey EP; Lowen GT; Almond MR
Biochemistry; 1998 Jun; 37(25):9043-51. PubMed ID: 9636049
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic properties and physiological roles of cytosolic 5'-nucleotidase II.
Itoh R
Curr Med Chem; 2013; 20(34):4260-84. PubMed ID: 23992315
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analogues.
Gallier F; Lallemand P; Meurillon M; Jordheim LP; Dumontet C; Périgaud C; Lionne C; Peyrottes S; Chaloin L
PLoS Comput Biol; 2011 Dec; 7(12):e1002295. PubMed ID: 22174667
[TBL] [Abstract][Full Text] [Related]
14. Distinct roles for recombinant cytosolic 5'-nucleotidase-I and -II in AMP and IMP catabolism in COS-7 and H9c2 rat myoblast cell lines.
Sala-Newby GB; Freeman NV; Skladanowski AC; Newby AC
J Biol Chem; 2000 Apr; 275(16):11666-71. PubMed ID: 10766785
[TBL] [Abstract][Full Text] [Related]
15. Active and regulatory sites of cytosolic 5'-nucleotidase.
Pesi R; Allegrini S; Careddu MG; Filoni DN; Camici M; Tozzi MG
FEBS J; 2010 Dec; 277(23):4863-72. PubMed ID: 21029378
[TBL] [Abstract][Full Text] [Related]
16. Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy.
Mazzon C; Rampazzo C; Scaini MC; Gallinaro L; Karlsson A; Meier C; Balzarini J; Reichard P; Bianchi V
Biochem Pharmacol; 2003 Aug; 66(3):471-9. PubMed ID: 12907246
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic studies on bovine cytosolic 5'-nucleotidase II, an enzyme belonging to the HAD superfamily.
Allegrini S; Scaloni A; Careddu MG; Cuccu G; D'Ambrosio C; Pesi R; Camici M; Ferrara L; Tozzi MG
Eur J Biochem; 2004 Dec; 271(23-24):4881-91. PubMed ID: 15606776
[TBL] [Abstract][Full Text] [Related]
18. Cytosolic 5'-nucleotidase II interacts with the leucin rich repeat of NLR family member Ipaf.
Cividini F; Tozzi MG; Galli A; Pesi R; Camici M; Dumontet C; Jordheim LP; Allegrini S
PLoS One; 2015; 10(3):e0121525. PubMed ID: 25811392
[TBL] [Abstract][Full Text] [Related]
19. Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models.
Jordheim LP; Puy JY; Cros-Perrial E; Peyrottes S; Lefebvre I; Périgaud C; Dumontet C
Anal Bioanal Chem; 2015 Jul; 407(19):5747-58. PubMed ID: 25998135
[TBL] [Abstract][Full Text] [Related]
20. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
Månsson E; Spasokoukotskaja T; Sällström J; Eriksson S; Albertioni F
Cancer Res; 1999 Dec; 59(23):5956-63. PubMed ID: 10606241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
